Ainos, Inc. (AIMD) Stock Price & Analysis
Ainos, Inc. (AIMD) rose 2.56% to USD 1.6 as of September 8, 2026 at 06:58 UTC, according to Nexqual real-time market data.
AIMD last closed at USD 1.6; the session ranged USD 1.51–1.65 on volume of 46,310 shares. Market capitalization is —, with a 52-week range of USD 1.26–4.44 (NCM). Source: Nexqual, September 8, 2026 at 06:58 UTC.
Key Statistics (as of September 8, 2026 at 06:58 UTC)
| Price | USD 1.6 |
|---|---|
| Change | ▲ 2.56% (up) |
| Previous Close | USD 1.6 |
| Open | USD 1.6 |
| Day Range | USD 1.51 – 1.65 |
| 52-Week Range | USD 1.26 – 4.44 |
| Volume | 46,310 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (AIMD)
Nexqual's technical model rates AIMD "BUY" based on 4 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 06:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.36 (neutral) |
| vs SMA50 | Above (USD 1.57) |
| MACD | -0 (negative) |
From Ainos, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Ltd. and its Taiwan subsidiary, Taiwan Inabata Sangyo Co., Topco Scientific Co., Ltd., Trusval Technology Co., Ltd., Solomon Technology Corporation, Kenmec Mechanical Engineering Co., Ltd., and Topmed International Biotech Co., Ltd.   Intellectual Property   We seek to protect our technology and competitive position through a combination of patents, trade secrets, proprietary know-how, and other intellectual property rights.
- Our approach emphasizes expanding the role of scent as a machine-readable data modality alongside vision and sound, while maintaining flexibility to address diverse operational requirements.   Separately, we continue to develop VELDONA®, our low-dose oral interferon platform, targeting selected rare, autoimmune, and infectious disease indications.
- We also believe that maintaining operations in Taiwan in the near term enables us to access technical and scientific talent while managing operating costs, supporting the development of high-quality and cost-effective products.   Outsourced Manufacturing.
- We rely on an outsourced manufacturing model, which we believe allows us to manage capital efficiently and maintain operational flexibility.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.1 | ▲ 4.04% |
| BBLG | Bone Biologics Corp | USD 0.57 | ▲ 3.27% |
| ACON | Aclarion, Inc. | USD 2.35 | ▲ 1.73% |
| SPRC | SciSparc Ltd. | USD 5.29 | ▼ 9.57% |
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.86 | ▲ 1.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:58 UTC. This page is informational and not investment advice.